



BioCAD

The First Computer-Aided Design Platform for Biology




Transforming biology from a process of discovery to a process of design.

Built by Deep Tech & R&D Leaders



Josh Reuben, CTO

20+ Years Deep Tech. AI Architect.
Bioinformatics Expert.



Or Maman, CEO


15+ Years R&D Leadership.
Scale & Cloud Operations Expert

Hybrid Structure: Israel HQ + Eastern Europe R&D for maximum capital efficiency.


Biology Today is a Game of Probability

Transitioning from costly trial-and-error to deterministic biological engineering

Current Bio-R&D (Discovery)



The Engineering Standard (Design)






Making Biology Deterministic


- 
Predict:
 Input protein variants
 → Output 3D morphology.
- 
Reverse Engineer:
 Input desired shape
 → Output genetic edits.
- 
Simulate:
 Test millions of designs
 in-silico.

A \$1.01 Trillion Opportunity Across 6 Domains.

Total Addressable Market: \$1T+. Serviceable Market: \$19-48B.



Strategy: Revenue Before Regulation.



Domain 2: Validating the Platform with Crop Traits.



Application: Optimizing plant architecture (yield potential, drought tolerance).




Data Advantage: Trained on massive 3D phenotypic & multi-omics datasets.




Partners: Targeting Corteva, Syngenta & Bayer.



Regulatory Status: Streamlined pathways (CRISPR-edited crops).



Domain 2: Solving the CAR-T Manufacturing Crisis.



Problem: 30-50% failure rate in Cell Therapy manufacturing.



Solution: Predictive Quality Control based on morphology during production.



Value: Saving **\$400k+** per patient batch.



Regulatory Edge: Operates under **FDA PAT** framework (No 510k required).

Domain 3: Revolutionizing IVF & Diagnostics.




Application: Non-invasive prediction of oocyte quality and embryo success.




Strategy: International-first launch (Israel/Spain) to bypass FDA delays.



Impact: Increasing IVF success rates from ~35% to >50%.



A Multi-Stream Business Model.




AI HUB



BioCAD: Genetic engineering design software platform.

⇒ **Annomanotations.**




Pay-Per-Prediction



Revenue from individual predictive analyses and diagnostics.

⇒ **Annomanotations.**



**Gene Edit
Patent Royalties**




Recurring revenue from licensing partners and integrated software.

⇒ **Long-term Value**

The "Morphology-First" Moat

The only platform linking Protein Structure directly to Macroscopic Form



Validated Tech & Deep Ecosystem.


Proof-of-Concept in development. Design partner outreach active.

Tech Stack

BioCAD
Morphology
Engine

Geometric
Deep Learning

NVIDIA
BioNeMo /
AlphaFold3



Partners



**INCEPTION
PROGRAM**

Funding Needs & Projected Market Milestones

Capital Requirements by Phase and Market Opportunity

Funding Milestones



- **Phase 1: \$1.6 M Required (Pre-Seed)**
 - 0-18 Months
 - Validation (AgTech)



- **Phase 2: \$3-4 M Required (Seed)**
 - 18-36 Months
 - Scaling (Pharma QC)



- **Phase 3: \$50 M Required (Series A+)**
 - 36+ Months
 - Platform Dominance (Clinical)

Projected Market




TAM (Total Addressable Market)
1.01 Trillion Dollar



SAM (Serviceable Addressable Market)
38 Billion Dollar



SOM (Serviceable Obtainable Market)
240 Million Dollar



Join Us in Designing the Future of Biology

Partner with the first platform to turn biology from a black box of probability into a deterministic design discipline.

Seeking Strategic Partners & Smart Capital

Or Maman / Josh Reuben